Literature DB >> 28951377

[Surgical treatment of giant thymoma in a patient with myasthenia gravis].

Xu Wu1, Xiang Li, Chang-Jiang Feng, Wu-Jun Wang.   

Abstract

We report a case report of giant thymoma (17 cm×14 cm×4 cm) in a 32-year-old male patient with myasthenia gravis. Examinations revealed that the tumor invaded the mediastinum, blood vessels and pericardium, and was histologically classified as WHO type B1 and Masaoka stage III. The patient developed myasthenia gravis crisis after radical resection of the thymoma and appropriate treatments with tracheotomy were administered. The patient recovered and was discharged after a hospital stay for 252 days with a mechanical ventilation time of 102 days.

Entities:  

Year:  2017        PMID: 28951377      PMCID: PMC6765495     

Source DB:  PubMed          Journal:  Nan Fang Yi Ke Da Xue Xue Bao        ISSN: 1673-4254


  8 in total

1.  Adjuvant radiotherapy for completely resected stage 2 thymoma.

Authors:  Abigail T Berman; Leslie Litzky; Virginia Livolsi; Sunil Singhal; John C Kucharczuk; Joel D Cooper; Joseph R Friedberg; Tracey L Evans; James P Stevenson; James M Metz; Stephen M Hahn; Ramesh Rengan
Journal:  Cancer       Date:  2011-02-01       Impact factor: 6.860

2.  Treatment of Thymoma-Associated Myasthenia Gravis With Stereotactic Body Radiotherapy: A Case Report.

Authors:  Caroline M Lee; Jason D Lee; Lisa D Hobson-Webb; Richard S Bedlack; Joseph K Salama
Journal:  Ann Intern Med       Date:  2016-03-15       Impact factor: 25.391

Review 3.  A Review of the Place and Role of Radiotherapy in Thymoma.

Authors:  Dorothy C Lombe; Branislav Jeremic
Journal:  Clin Lung Cancer       Date:  2015-05-13       Impact factor: 4.785

4.  Postoperative radiotherapy after surgical resection of thymoma: differing roles in localized and regional disease.

Authors:  Jeffrey A Forquer; Nan Rong; Achilles J Fakiris; Patrick J Loehrer; Peter A S Johnstone
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-05-08       Impact factor: 7.038

5.  Adjuvant Radiotherapy for Stages II and III Resected Thymoma: A Single-institutional Experience.

Authors:  Jinchun Yan; Qin Liu; Jessica N Moseley; Christina S Baik; Laura Q M Chow; Bernardo H M Goulart; David Zlotnick; Antoni Papanicolau-Sengos; Ian Gallaher; Joy M Knopp; Jing Zeng; Shilpen Patel
Journal:  Am J Clin Oncol       Date:  2016-06       Impact factor: 2.339

Review 6.  Thymoma, myasthenia gravis, and other paraneoplastic syndromes.

Authors:  Laura M Tormoehlen; Robert M Pascuzzi
Journal:  Hematol Oncol Clin North Am       Date:  2008-06       Impact factor: 3.722

7.  Treatment and prognosis of type B2 thymoma.

Authors:  Zhengbo Song; Xiangyu Jin; Yiping Zhang
Journal:  World J Surg Oncol       Date:  2014-09-20       Impact factor: 2.754

8.  Case Report of Thymoma Tumor Reduction Following Plasmapheresis.

Authors:  Wei Jiang; Qitao Yu
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.